We are live on ! Find out more
ARIA

Ariad Pharmaceuticals Inc
ARIA

Delisted

ARIA was delisted on the 15th of February, 2017.

166 hedge funds and large institutions have $801M invested in Ariad Pharmaceuticals Inc in 2013 Q4 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 58 reducing their positions, and 88 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 24 (+2)

12% less repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 58

20% less funds holding

Funds holding: 208166 (-42)

26% less call options, than puts

Call options by funds: $35.5M | Put options by funds: $48.1M

48% less first-time investments, than exits

New positions opened: 46 | Existing positions closed: 88

72% less capital invested

Capital invested by funds: $2.85B → $801M (-$2.05B)

Holders
166
Holders Change
-42
Holders Change %
-20.19%
% of All Funds
4.82%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.12%
New
46
Increased
51
Reduced
58
Closed
88
Calls
$35.5M
Puts
$48.1M
Net Calls
-$12.6M
Net Calls Change
+$3.73M
Name Holding Trade Value Shares
Change
Change in
Stake
BBA
176
Baker Bros. Advisors
New York
-$24.5M -1,333,703 Closed
RG
177
Redmile Group
California
-$23.3M -1,264,009 Closed
DM
178
Deerfield Management
New York
-$22.6M -1,227,204 Closed
Brown Advisory
179
Brown Advisory
Maryland
-$19.5M -1,059,275 Closed
O
180
OppenheimerFunds
New York
-$18.4M -1,000,000 Closed
American Century Companies
181
American Century Companies
Missouri
-$16.9M -921,159 Closed
Jennison Associates
182
Jennison Associates
New York
-$16.4M -891,161 Closed
Lazard Asset Management
183
Lazard Asset Management
New York
-$13.8M -749,243 Closed
PCM
184
Palisade Capital Management
New Jersey
-$10.1M -550,142 Closed
CCP
185
Clough Capital Partners
Massachusetts
-$9.95M -540,500 Closed
OAM
186
Oxford Asset Management
United Kingdom
-$9.87M -536,211 Closed
Capital World Investors
187
Capital World Investors
California
-$9.57M -520,000 Closed
MNA
188
Manning & Napier Advisors
New York
-$9.28M -504,530 Closed
TCM
189
Tekla Capital Management
Massachusetts
-$7.6M -412,965 Closed
TG
190
TCW Group
California
-$7.4M -402,036 Closed
IG
191
ING Group
Netherlands
-$6.93M -376,668 Closed
CCI
192
Columbus Circle Investors
-$6.29M -341,756 Closed
CCM
193
Century Capital Management
Massachusetts
-$5.74M -311,806 Closed
Principal Financial Group
194
Principal Financial Group
Iowa
-$4.44M -241,230 Closed
TA
195
Teton Advisors
New York
-$4.27M -232,022 Closed
HCM
196
Highbridge Capital Management
New York
-$3.76M -204,450 Closed
Fidelity International
197
Fidelity International
Bermuda
-$3.47M -188,570 Closed
ARTA
198
A.R.T. Advisors
New York
-$3.37M -183,377 Closed
Lord, Abbett & Co
199
Lord, Abbett & Co
New Jersey
-$3.23M -175,734 Closed
PAMU
200
Pictet Asset Management (UK)
United Kingdom
-$3.08M -167,300 Closed

ARIA Hedge Fund Activity: Q4 2013 in Review

166 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Ariad Pharmaceuticals Inc (ARIA) for Q4 2013, worth a combined $801M — down 72% from $2.85B a quarter earlier.

Sellers outnumbered buyers: 88 funds closed out of ARIA and 46 opened new positions — a net loss of 42 holders — while 58 trimmed existing stakes and 51 added.

The largest buyer was Camber Capital Management, opening a new position worth an estimated $28.3M. The largest seller was Waddell & Reed Financial, exiting entirely with an estimated $106M sold.

  • 166 institutional investors held Ariad Pharmaceuticals Inc (ARIA) as of Q4 2013, down from 208 in Q3 2013.
  • Funds reported $801M of Ariad Pharmaceuticals Inc stock for Q4 2013, down 72% quarter-over-quarter.
  • 46 funds opened new Ariad Pharmaceuticals Inc positions in Q4 2013 and 88 closed out, a net change of -42 holders.
  • The largest Ariad Pharmaceuticals Inc buyer in Q4 2013 was Camber Capital Management, an estimated $28.3M added.
  • The largest Ariad Pharmaceuticals Inc seller in Q4 2013 was Waddell & Reed Financial, an estimated $106M sold.

Based on aggregated 13F filings for Q4 2013.